John Pedersen

Pedersen most recently served as CEO of Augmenix, which was sold to Boston Scientific in 2018. Prior to Augmenix, he was a senior healthcare advisor for two healthcare private equity funds – The Gores Group and The Pritzker Group. Earlier, he was president of the Urology and Women’s Health Division at Boston Scientific. 

  • March 2020

Added to: DYSIS Medical - Alpharetta, GA

DYSIS Medical is committed to early detection and diagnosis of cervical disease using biophotonic innovations. They are a leader in automated optical molecular imaging technologies for medical diagnostic and screening applications.